Clinicopathological values of NBS1 and DNA damage response genes in epithelial ovarian cancers

다국어 초록 (Multilingual Abstract)

Epithelial ovarian cancers (EOCs) are highly lethal gynecological malignancies with a high recurrence rate. Therefore, developing prognostic markers for recurrence after chemotherapy is crucial for the treatment of ovarian cancers. As ovarian cancers frequently respond to DNA-damaging agents, we assessed the clinicopathological significance of key double-strand DNA break (DSB) repair genes, including BRCA1, BRCA2, BARD1, ATM, RAD51 and NBS1 in EOC cell lines and paraffin-embedded tissue sections from 140 EOC patients treated with cytoreductive surgery, followed by platinum-based chemotherapy. These samples were analyzed for the clinicopathological impact of DSB genes by western blot analysis, immunohistochemistry and quantitative real-time PCR. Of the DSB repair genes, BRCA1, ATM and NBS1, which are involved in the homologous recombinationmediated repair pathway, were related to aggressive parameters in EOC. When survival analysis was performed, NBS1 expression exhibited an association with EOC recurrence. Specifically, increased NBS1 expression was found in 107 out of 140 cases (76.0%) and correlated with advanced stage (P=0.001), high grade (P=0.001) and serous histology (P=0.008). The median recurrence-free survival in patients with positive and negative expression of NBS1 was 30 and 78 months, respectively (P=0.0068). In multivariate analysis, NBS1 was an independent prognostic factor for the recurrence of EOC. Together, these results suggest that NBS1 is a marker of poor prognosis for the recurrence of EOC and is associated with aggressive clinicopathological parameters.

참고문헌 (Reference)

1 Drew Y, "Therapeutic potential of poly(ADP-ribose)polymerase inhibitor AG014699in human cancers with mutated or methylated BRCA1 or BRCA2" 103 : 334-346, 2011

2 Demuth I, "The clinical manifestation of a defective response to DNA double-strand breaks as exemplified by Nijmegen breakage syndrome" 26 : 7792-7798, 2007

3 D'Andrea AD, "The Fanconi anaemia/BRCA pathway" 3 : 23-34, 2003

4 D'Andrea AD., "The Fanconi Anemia/BRCA signaling pathway: disruption in cisplatin-sensitive ovarian cancers" 2 : 290-292, 2003

5 Foster KA, "Somatic and germline mutations of the BRCA2 gene in sporadic ovarian cancer" 56 : 3622-3625, 1996

6 Vasey PA, "Resistance to chemotherapy in advanced ovarian cancer:mechanisms and current strategies" 89 (89): S23-S28, 2003

7 Kim H, "Regulation of DNA cross-link repair by the Fanconi anemia/BRCA pathway" 26 : 1393-1408, 2012

8 Auranen A, "Polymorphisms in DNA repair genes and epithelial ovarian cancer risk" 117 : 611-618, 2005

9 Lu J, "Polymorphisms and haplotypes of the NBS1 gene are associated with risk of sporadic breast cancer in non-Hispanic white women oor=55 years" 27 : 2209-2216, 2006

10 Fong PC, "Poly(ADP)-ribose polymerase inhibition : frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval" 28 : 2512-2519, 2010

11 Paull TT., "Mechanisms of ATM Activation" 84 : 711-738, 2015

12 Yang MH, "Increased NBS1 expression is a marker of aggressive head and neck cancer and overexpression of NBS1 contributes to transformation" 12 : 507-515, 2006

13 Hilton JL, "Inactivation of BRCA1 and BRCA2 in ovarian cancer" 94 : 1396-1406, 2002

14 Hsu DS, "Identification of increased NBS1 expression as a prognostic marker of squamous cell carcinoma of the oral cavity" 101 : 1029-1037, 2010

15 Turner N, "Hallmarks of 'BRCAness' in sporadic cancers" 4 : 814-819, 2004

16 Jiang L, "Functional polymorphisms in the NBS1 gene and acute lymphoblastic leukemia susceptibility in a Chinese population" 86 : 199-205, 2011

17 Zheng J, "Functional NBS1polymorphism is associated with occurrence and advanced disease status of nasopharyngeal carcinoma" 50 : 689-696, 2011

18 Geisler JP, "Frequency of BRCA1dysfunction in ovarian cancer" 94 : 61-67, 2002

19 Tutt AN, "Exploiting the DNA repair defect in BRCA mutant cells in the design of new therapeutic strategies for cancer" 70 : 139-148, 2005

20 Kristensen GB, "Epithelial ovarian carcinoma" 349 : 113-117, 1997

21 Lee JH, "Direct activation of the ATM protein kinase by the Mre11/Rad50/Nbs1 complex" 304 : 93-96, 2004

22 Mukhopadhyay A, "Development of a functional assay for homologous recombination status in primary cultures of epithelial ovarian tumor and correlation with sensitivity to poly(ADP-ribose)polymerase inhibitors" 16 : 2344-2351, 2010

23 Lee H, "Cycling with BRCA2 from DNA repair to mitosis" 329 : 78-84, 2014

24 Teodoridis JM, "CpG island methylation of DNA damage response genes in advanced ovarian cancer" 65 : 8961-8967, 2005

25 Broberg K, "Constitutional short telomeres are strong genetic susceptibility markers for bladder cancer" 26 : 1263-1271, 2005

26 Siegel R, "Cancer statistics, 2014" 64 : 9-29, 2014

27 Baldwin RL, "BRCA1 promoter region hypermethylation in ovarian carcinoma : a population-based study" 60 : 5329-5333, 2000

28 Cho S, "Associations between polymorphisms in DNA repair genes and TP53 mutations in nonsmall cell lung cancer" 73 : 25-31, 2011

29 Stordal B, "A systematic review of genes involved in the inverse resistance relationship between cisplatin and paclitaxel chemotherapy : role of BRCA1" 9 : 354-365, 2009